A1: no patient specific details have been provided.Therefore, the patient identifier reflects the study number with codes for the hospital and patient.H3: other: engineering evaluation could not be performed as the device remains implanted.H6: evaluation codes investigation findings c19 refers to the product history review: a review of the manufacturing records indicated the lots met pre-release specifications.As primary relationship study-device related is mentioned in the study database.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
The following was reported to gore on 1/22/2024 from the viedoc study database: on (b)(6) 2024, this 68-year-old patient underwent tips procedure for pre-operative tips and ascites.The patient was treated with a cook device and gore® viatorr® tips endoprosthesis with controlled expansion device to the portal vein.The study device was successfully delivered during the procedure.On (b)(6) 2024, it was noted the patient had hepatic encephalopathy grade 1 related to the gore® viatorr® tips endoprosthesis with controlled expansion device.Inpatient or prolonged hospitalization was required for medical intervention using medication.On (b)(6) 2024, the patient was noted to have recovered/resolved without sequelae.
|
Neither clinical images enabling direct assessment of product performance nor the device was returned for evaluation.This complaint was initiated based on information received from a study.The data provided within the study database were reviewed.No further information was provided to gore.An adverse event appears to have occurred, but there does not appear to have been a problem with the device or the way it was used.No allegation of device malfunction was indicated with respect to device performance.In the ifu for the gore® viatorr® tips endoprosthesis with controlled expansion the following is stated: adverse events potential clinical and device adverse events.Possible adverse events and complications that may occur with the use of any gore® viatorr® tips endoprosthesis with controlled expansion or in any tips procedure and require intervention may include, but are not limited to: new onset or worsened hepatic encephalopathy.
|